CClinicalTrials.gg
RecruitingNCT07116564Updated Feb 17, 2026

Impact of ERAS Protocol on Length of Hospital Stay After Laparoscopic Surgeries

A Phase 4 interventional study of Enhanced Recovery After Surgery and Control in ERAS, sponsored by Aga Khan University. Recruiting at 1 site in Pakistan. Open to female participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Aga Khan University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 1 month later.
Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to determine the length of hospital stay in patients using multimodal analgesia with or without ERAS protocol scheduled for elective laparoscopic gynecological surgeries

02

Conditions studied

  • ERAS
03

In context

Lead sponsor

Aga Khan University is the lead sponsor of 290 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • ASA physical status I, II, and III
  • Patients scheduled for elective laparoscopic gynecological surgeries

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • History of allergy or contraindication to study drugs
  • Patients in which procedure converted to open surgery
  • Diagnostic laparoscopic procedures
  • Patients with a history of severe anxiety or depression
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Active comparator
    Group C

    Drug: Control

  • Experimental
    Group E

    Drug: Enhanced Recovery After Surgery

Interventions

  • DrugEnhanced Recovery After Surgery

    Preoperatively ERAS protocol includes, No solid food for 6 hours before procedure; 800 ml (fantomalt powder) Carbohydrate drink 8 hours before surgery; 400 ml (fantomalt powder) 2 hours before surgery; Celecoxib 200g 1 hour before surgery . Intraoperatively, on induction lidocaine 1.5 mg/kg and Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion at 1.5 mg/kg/h.

  • DrugControl

    Preoperatively, NPO 6 hours before the procedure Intraoperatively, on induction Nabuphine 0.1mg/kg

06

What researchers measure

Primary outcomes

  1. Length of hospital stay

    Post-operative length of hospital stay, measured in hours from the patient's arrival in the recovery room until 72 hours after surgery.

    Time frame: From arrival in the recovery room post-surgery until 72 hours after surgery.

Secondary outcomes

  1. Postoperative pain score

    Post operative pain score will be measures using NRS (Numerical Rating Scale). Eleven points pain scale measures from 0-10, where "0" is no pain and "10" is the worst possible pain

    Time frame: 4 hours, 8 hours, 12 hours, 24 hours, 48 hours & 72 hours postoperatively

  2. Amount of opioid used in patient controlled analgesia

    Total Nalbuphine consumption in 12 hours (in milligrams)

    Time frame: 12 hours postoperatively.

  3. Patient satisfaction Score

    Patient satisfaction with the pain management regimen will be assessed using a five-point Likert scale 24 hours after surgery. The scale ranges from 1 to 5, where 1 = Very Dissatisfied, 2 = Dissatisfied, 3 = Neutral, 4 = Satisfied, and 5 = Very Satisfied. Higher scores indicate greater satisfaction.

    Time frame: 24 hours after the operation

07

Study locations

1 of 1 sites recruiting
  • Aga Khan University, Karachi, Pakistan
    Karachi, Sindh, Pakistan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07116564
Lead sponsor
Aga Khan University
Responsible party
Ali Sarfraz Siddiqui (Assistant Professor, Aga Khan University) — Principal investigator
First posted
Aug 11, 2025
Start date
Aug 20, 2025
Primary completion
Aug 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Ali Sarfraz Siddiqui, MBBS, MCPS, FCPS, FIPP, MHPE
Contact
sarfraz.siddiqui@aku.edu
+922134864397 ext. 4397

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion